These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 9517948

  • 1. Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept.
    Firsov AA, Shevchenko AA, Vostrov SN, Zinner SH.
    Antimicrob Agents Chemother; 1998 Mar; 42(3):659-65. PubMed ID: 9517948
    [Abstract] [Full Text] [Related]

  • 2. MIC-based interspecies prediction of the antimicrobial effects of ciprofloxacin on bacteria of different susceptibilities in an in vitro dynamic model.
    Firsov AA, Vostrov SN, Shevchenko AA, Zinner SH, Cornaglia G, Portnoy YA.
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2848-52. PubMed ID: 9797214
    [Abstract] [Full Text] [Related]

  • 3. A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities.
    Firsov AA, Vostrov SN, Shevchenko AA, Portnoy YA, Zinner SH.
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2841-7. PubMed ID: 9797213
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model.
    Firsov AA, Vasilov RG, Vostrov SN, Kononenko OV, Lubenko IY, Zinner SH.
    J Antimicrob Chemother; 1999 Apr; 43(4):483-90. PubMed ID: 10350376
    [Abstract] [Full Text] [Related]

  • 7. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
    Zinner SH, Vostrov SN, Alferova IV, Lubenko IY, Portnoy YA, Firsov AA.
    Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
    [Abstract] [Full Text] [Related]

  • 8. Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses.
    Firsov AA, Lubenko IY, Vostrov SN, Kononenko OV, Zinner SH, Portnoy YA.
    J Antimicrob Chemother; 2000 Nov; 46(5):725-32. PubMed ID: 11062191
    [Abstract] [Full Text] [Related]

  • 9. Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses.
    Firsov AA, Zinner SH, Lubenko IYu, Vostrov SN.
    Int J Antimicrob Agents; 2000 Dec; 16(4):407-14. PubMed ID: 11118849
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Bacterial strain-independent AUC/MIC and strain-specific dose-response relationships reflecting comparative fluoroquinolone anti-pseudomonal pharmacodynamics in an in vitro dynamic model.
    Lubenko IY, Vostrov SN, Portnoy YA, Zinner SH, Firsov AA.
    Int J Antimicrob Agents; 2002 Jul; 20(1):44-9. PubMed ID: 12127710
    [Abstract] [Full Text] [Related]

  • 12. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model.
    Madaras-Kelly KJ, Ostergaard BE, Hovde LB, Rotschafer JC.
    Antimicrob Agents Chemother; 1996 Mar; 40(3):627-32. PubMed ID: 8851583
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin.
    Firsov AA, Zinner SH, Vostrov SN, Portnoy YA, Lubenko IY.
    J Antimicrob Chemother; 2002 Oct; 50(4):533-9. PubMed ID: 12356798
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial susceptibility.
    MacGowan AP, Wootton M, Holt HA.
    J Antimicrob Chemother; 1999 Mar; 43(3):345-9. PubMed ID: 10223589
    [Abstract] [Full Text] [Related]

  • 20. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I, Cars O.
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.